Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Combined Varicella and Hepatitis A Vaccines in Toddlers
NCT05526820Phase 4Completed
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Apr 2021
- Primary completion
- Apr 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of varicella virus vaccine live and hepatitis A vaccine (inactivated) in varicella (VZV) and hepatitis A (HAV) (2 arms), sponsored by Sinovac Biotech Ltd. Primary endpoints: Seroconversion rates of the varicella antibody at 42 days and Seroconversion rates of anti-HAV antibody. Started Apr 2021; status: completed.
02
Drugs
varicella virus vaccine livehepatitis A vaccine (inactivated)
03
Conditions
varicella (VZV)hepatitis A (HAV)
Beyond the preview
Go deeper on NCT05526820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05526820.